We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IF0 market cap is 67.07M. The company's latest EPS is EUR -0.7246 and P/E is -1.70.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 400k | 222k | 54k | 20.16M | 63k |
| Operating Income | -56.77M | -33.94M | -47.63M | -32.24M | -44.91M |
| Net Income | -53.26M | -33.98M | -45.63M | -29.48M | -42.67M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 121.58M | 88.22M | 125.14M | 102.4M | 120.21M |
| Total Liabilities | 14.43M | 10.35M | 19.86M | 14.05M | 17.63M |
| Total Equity | 107.15M | 77.86M | 105.28M | 88.35M | 102.58M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -43.2M | -36.53M | -39.94M | -33.74M | -37.81M |
| Investing | 20.34M | 21.36M | -25.95M | 19.36M | -17.7M |
| Financing | -294k | 9.17M | 61.58M | 1.94M | 52.99M |
| Market Cap | 67.07M |
| Price to Earnings Ratio | -1.70 |
| Price to Sales Ratio | 1.12k |
| Price to Cash Ratio | 5.67 |
| Price to Book Ratio | 0.71 |
| Dividend Yield | - |
| Shares Outstanding | 58.88M |
| Average Volume (1 week) | 34.52k |
| Average Volume (1 Month) | 58.95k |
| 52 Week Change | -22.31% |
| 52 Week High | 2.70 |
| 52 Week Low | 1.061 |
| Spread (Intraday) | 0.03 (2.63%) |
| Company Name | InflaRx NV |
| Address |
winzerlaer jena 07745 |
| Website | https://www.inflarx.de |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
